Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 3, 2013, Pages 269-277

  Evstatiev, Rayko ^a   Alexeeva, Olga ^b   Bokemeyer, Bernd ^c   Chopey, Ivan ^d   Felder, Marcel ^e   Gudehus, Maja ^e   Iqbal, Tariq ^f   Khalif, Igor ^g   Marteau, Philippe ^h   Stein, Jürgen ⁱ   Gasche, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Regional Clinical Hospital   (Russian Federation)

^c KLINIKUM MINDEN   (Germany)

^d National University   (Ukraine)

^e Vifor (International) Inc   (Switzerland)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g State Scientific Centre of Coloproctology   (Russian Federation)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ Department of Gastroenterology and Clinical Nutrition ^*  (Germany)

Author keywords

Crohn's Disease; Intravenous Iron; Iron Maintenance Treatment; Ulcerative Colitis

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; PLACEBO; TRANSFERRIN;

ADULT; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE REACTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANEMIA, IRON-DEFICIENCY; DIETARY SUPPLEMENTS; FEMALE; FERRIC COMPOUNDS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MALTOSE; MIDDLE AGED; PLACEBOS; RECURRENCE; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874568807     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.10.013     Document Type: Article

References (29)

1. Worldwide prevalence of anaemia 1993-2005 2008, WHO, World Health Organization, Geneva, Switzerland.
2. Kulnigg S., Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006, 24:1507-1523.
3. Qunibi W.Y. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010, 60:399-412.
4. Gasche C., Lomer M.C., Cavill I., et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004, 53:1190-1197.
5. Gisbert J.P., Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008, 103:1299-1307.
6. Graff L.A., Vincent N., Walker J.R., et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:1882-1889.
7. Stein J., Hartmann F., Dignass A.U. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010, 7:599-610.
8. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
9. Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448.
10. Brownlie T., Utermohlen V., Hinton P.S., et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004, 79:437-443.
11. Krayenbuehl P.A., Battegay E., Breymann C., et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011, 118:3222-3227.
12. Verdon F., Burnand B., Stubi C.L., et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003, 326:1124.
13. Wells C.W., Lewis S., Barton J.R., et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006, 12:123-130.
14. Evstatiev R., Marteau P., Iqbal T., et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011, 141:846-853.
15. Gasché C., Dejaco C., Waldhoer T., et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997, 126:782-787.
16. Kulnigg S., Stoinov S., Simanenkov V., et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008, 103:1182-1192.
17. Gasche C., Berstad A., Befrits R., et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007, 13:1545-1553.
18. Gasche C., Evstatiev R., Haas T., et al. [Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]. Z Gastroenterol 2011, 49:627-632.
19. Kulnigg S., Teischinger L., Dejaco C., et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009, 104:1460-1467.
20. Ware J.E., Kosinski M., Dewey J.E. How to score version 2 of the SF-36 Health Survey 2001, QualityMetric, Inc, Lincoln, RI. 3rd ed.
21. Irvine E.J., Feagan B., Rochon J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-296.
22. Brutsaert T.D., Hernandez-Cordero S., Rivera J., et al. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr 2003, 77:441-448.
23. Hinton P.S., Sinclair L.M. Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2007, 61:30-39.
24. Nissenson A.R., Wade S., Goodnough T., et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005, 11:565-574.
25. Weiss G., Fuchs D., Hausen A., et al. Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol 1992, 20:605-610.
26. Weiss G., Werner-Felmayer G., Werner E.R., et al. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994, 180:969-976.
27. Bartels U., Pedersen N.S., Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol 1978, 13:649-656.
28. Hansen T.M., Hansen N.E., Birgens H.S., et al. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. Scand J Rheumatol 1983, 12:353-359.
29. Lindgren S., Wikman O., Befrits R., et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009, 44:838-845.